JP2024518335A5 - - Google Patents
Info
- Publication number
- JP2024518335A5 JP2024518335A5 JP2023566420A JP2023566420A JP2024518335A5 JP 2024518335 A5 JP2024518335 A5 JP 2024518335A5 JP 2023566420 A JP2023566420 A JP 2023566420A JP 2023566420 A JP2023566420 A JP 2023566420A JP 2024518335 A5 JP2024518335 A5 JP 2024518335A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- light chain
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2021000314 | 2021-04-26 | ||
| IBPCT/IB2021/000314 | 2021-04-26 | ||
| EP21306908 | 2021-12-22 | ||
| EP21306908.1 | 2021-12-22 | ||
| IB2022000108 | 2022-02-25 | ||
| IBPCT/IB2022/000108 | 2022-02-25 | ||
| PCT/EP2022/058777 WO2022228827A1 (en) | 2021-04-26 | 2022-04-01 | Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024518335A JP2024518335A (ja) | 2024-05-01 |
| JP2024518335A5 true JP2024518335A5 (https=) | 2025-03-24 |
Family
ID=81328034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566420A Pending JP2024518335A (ja) | 2021-04-26 | 2022-04-01 | ＳＡＲＳ－ＣｏＶ－２に対するヒト中和モノクローナル抗体、及びそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240336672A1 (https=) |
| EP (1) | EP4330278A1 (https=) |
| JP (1) | JP2024518335A (https=) |
| KR (1) | KR20240006575A (https=) |
| WO (1) | WO2022228827A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024061759A1 (en) * | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized coronavirus s proteins |
| CN120129695A (zh) * | 2022-12-20 | 2025-06-10 | 北京昌平实验室 | 新型冠状病毒xbb.1.5及相关变异株广谱中和抗体及应用 |
| CN120035605A (zh) * | 2022-12-20 | 2025-05-23 | 北京昌平实验室 | 新型冠状病毒奥密克戎突变株广谱中和抗体及应用 |
| EP4442276A1 (en) | 2023-04-07 | 2024-10-09 | Institut Pasteur | Combined antibodies against sarbecoviruses and uses thereof |
| WO2025140539A1 (en) * | 2023-12-29 | 2025-07-03 | The University Of Hong Kong | Ultrapotent broardly neutralizing antibodies against sars-cov-2 variants and methods of use thereof |
| WO2025153707A1 (en) | 2024-01-19 | 2025-07-24 | Spikimm | Broadly sars-cov-2 neutralizing monoclonal antibodies and uses thereof |
| WO2025153835A1 (en) * | 2024-01-19 | 2025-07-24 | Spikimm | Broadly sars-cov-2 neutralizing monoclonal antibodies and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| EP2755986A4 (en) | 2011-09-12 | 2015-05-20 | Moderna Therapeutics Inc | MANIPULATED NUCLEIC ACIDS AND METHOD OF APPLICATION THEREFOR |
| US9950065B2 (en) | 2013-09-26 | 2018-04-24 | Biontech Rna Pharmaceuticals Gmbh | Particles comprising a shell with RNA |
| PL4023249T3 (pl) | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| US10626400B2 (en) | 2014-07-04 | 2020-04-21 | Biontech Ag | Stabilised formulations of RNA |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
| SI3445850T1 (sl) | 2016-04-22 | 2021-12-31 | BioNTech SE | Postopki za zagotavljanje enoverižne RNA |
| WO2018010815A1 (en) | 2016-07-15 | 2018-01-18 | Biontech Rna Pharmaceuticals Gmbh | Formulation for administration of rna |
| KR20200109310A (ko) | 2018-01-11 | 2020-09-22 | 비온테크 알엔에이 파마슈티컬스 게엠베하 | Rna의 투여를 위한 제형 |
| KR20200143391A (ko) | 2018-03-15 | 2020-12-23 | 비온테크 알엔에이 파마슈티컬스 게엠베하 | 5'-캡-트리뉴클레오티드- 또는 고차의 올리고뉴클레오티드 화합물 및 이들의 rna 안정화, 단백질 발현 및 치료에서의 사용 |
| WO2021001023A1 (en) | 2019-07-02 | 2021-01-07 | Biontech Rna Pharmaceuticals Gmbh | Rna formulations suitable for therapy |
| KR20250107297A (ko) * | 2020-04-02 | 2025-07-11 | 리제너론 파아마슈티컬스, 인크. | 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편 |
| CN111690059B (zh) * | 2020-06-19 | 2022-03-08 | 武汉生物制品研究所有限责任公司 | 一种抗SARS-CoV-2的单克隆抗体1D7 |
| CN117003862B (zh) * | 2020-08-19 | 2024-08-20 | 重庆医科大学 | 新冠病毒rbd特异性单克隆抗体和应用 |
| CN111909260B (zh) * | 2020-08-19 | 2022-06-21 | 重庆医科大学 | 新冠病毒rbd特异性单克隆抗体和应用 |
-
2022
- 2022-04-01 US US18/288,115 patent/US20240336672A1/en active Pending
- 2022-04-01 EP EP22714897.0A patent/EP4330278A1/en active Pending
- 2022-04-01 JP JP2023566420A patent/JP2024518335A/ja active Pending
- 2022-04-01 WO PCT/EP2022/058777 patent/WO2022228827A1/en not_active Ceased
- 2022-04-01 KR KR1020237040527A patent/KR20240006575A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024518335A5 (https=) | ||
| EP2265643B1 (en) | Dosing regimen for treating psoriasis and rheumatoid arthritis | |
| KR101671452B1 (ko) | 항ｒｓｖ ｇ 단백질 항체 | |
| CN112166121B (zh) | 神经生长因子的单克隆抗体及其编码基因和应用 | |
| EP3360896B1 (en) | Antibody to hepatitis b surface antigen and use thereof | |
| TW202228776A (zh) | 抗tslp抗體藥物組合物及其用途 | |
| EP2308895A1 (en) | Anti-HSV antibody | |
| EP3858857A1 (en) | An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use | |
| CN117843789A (zh) | 治疗性抗cd40配体抗体 | |
| CN112079922B (zh) | 抗人p40蛋白域抗体及其用途 | |
| JP2018509147A (ja) | 抗スクレロスチン抗体、その抗原結合フラグメントおよびその医薬用途 | |
| TW202114688A (zh) | Ｔｌｒ激動劑與抗ｏｘ４０抗體或其抗原結合片段聯合在製備治療腫瘤的藥物中的用途 | |
| US12466877B2 (en) | Metallothionein antibodies and their use | |
| CN114269788B (zh) | 一种能够与人4-1bb结合的分子及其应用 | |
| JP2026501152A (ja) | ＴＮＦ－α及びＩＬ－１７Ａを標的とする二重特異性融合タンパク質及びその使用 | |
| TW202144005A (zh) | 一種抗ｏｘ４０抗體醫藥組成物及其用途 | |
| US20260125471A1 (en) | Subcutaneous administration of antibodies for the treatment of disease | |
| US20220332822A1 (en) | Subcutaneous administration of antibodies for the treatment of disease | |
| CN116041492B (zh) | 一种抗rbd抗体及其应用 | |
| US20240228594A1 (en) | Antibodies for the treatment and prevention of covid-19 and emerging variants | |
| WO2024085207A1 (ja) | ベータコロナウイルスに対するウマ抗血清 | |
| TW202426053A (zh) | 單純皰疹病毒感染的治療 | |
| CN121824774A (zh) | 一种治疗李斯特菌病的双特异性抗体及其药物组合物 | |
| HK40045557A (en) | An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use | |
| HK1184168B (en) | Antagonist anti-il-7 receptor antibodies and methods |